NR3C2基因型与醛固酮拮抗剂在舒张性心衰中的疗效关联
本研究为Aldo-DHF试验的事后遗传分析,纳入184例螺内酯组和178例安慰剂组患者,探讨NR3C2和CYP11B2基因多态性与螺内酯反应的关系。结果显示,在安慰剂组中,NR3C2 rs5522 G等位基因携带者12个月内E/e'增加更明显(β=1.10,95%CI 0.05-2.16,p=0.04),而螺内酯组无此恶化。提示螺内酯可能减轻与rs5522 G等位基因相关的舒张功能障碍进展,但需验证。
要点
- NR3C2 rs5522 G等位基因携带者安慰剂组E/e'恶化更明显,螺内酯组无此现象。
- rs5522 G携带者安慰剂组左房面积增加更多,螺内酯组舒张压下降更显著。
- 其他SNP(rs2070951、rs1799998)与E/e'变化无关,PIIINP水平在各基因型间相似。
核心结论
- 螺内酯可能减弱NR3C2 rs5522 G等位基因相关的舒张功能障碍进展。
- 该发现需进一步验证。
研究设计与样本
- Aldo-DHF试验的事后遗传分析,多中心、随机、双盲、安慰剂对照。
- 纳入螺内酯组184例和安慰剂组178例,对NR3C2 rs5522、rs2070951和CYP11B2 rs1799998进行基因分型。
主要发现
- 安慰剂组中,rs5522 G携带者12个月E/e'增加较非携带者更大(β=1.10;95%CI 0.05-2.16;p=0.04)。
- 螺内酯组中,rs5522基因型与E/e'变化无显著关联。
- 其他基因型与E/e'变化无关。
- rs5522 G携带者安慰剂组左房面积增加更大(β=0.83;95%CI 0.17-1.48;p=0.01),螺内酯组舒张压下降更大(β=-3.56;95%CI -6.73至-0.39;p=0.03)。
- 血清PIIINP水平在各rs5522基因型间相似。
关键数值与推荐
- NR3C2 rs5522 G等位基因可能作为螺内酯在舒张性心衰中疗效的潜在生物标志物。
临床怎么用
- 对于携带NR3C2 rs5522 G等位基因的舒张性心衰患者,螺内酯可能减缓舒张功能恶化。
- 目前证据尚不足以常规推荐基因分型指导螺内酯用药,需等待验证性研究。
局限性
- 事后遗传分析,结果需独立验证。
- 样本量有限,仅纳入Aldo-DHF试验人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: This study aimed to determine if variants in NR3C2, which codes the target protein of spironolactone, or CYP11B2, which is involved in aldosterone synthesis, were associated with spironolactone response, focused on the primary end point of diastolic function (E/e'), in Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) participants. DESIGN: Post-hoc genetic analysis. DATA SOURCE: Data and samples were derived from the multi-center, randomized, double-blind, placebo-controlled Aldo-DHF trial. PATIENTS: Aldo-DHF participants treated with spironolactone (n = 184) or placebo (n = 178) were included. INTERVENTION: Participants were genotyped for NR3C2 rs5522, NR3C2 rs2070951 and CYP11B2 rs1799998 via pyrosequencing. MEASUREMENTS: In the placebo and spironolactone arms, separate multivariable linear regression analyses were performed for change in E/e' with each single nucleotide polymorphism (SNP), adjusted for age, sex, and baseline E/e'. To discern potential mechanisms of a genotype effect, associated SNPs were further examined for their association with change in blood pressure, circulating procollagen type III N-terminal peptide (PIIINP), and left atrial area. MAIN RESULTS: Carriers of the rs5522 G allele in the placebo arm had a greater increase in E/e' over the 12-month course of the trial compared to noncarriers (β = 1.10; 95% confidence interval [CI]: 0.05-2.16; p = 0.04). No corresponding E/e' worsening by rs5522 genotype was observed in the spironolactone arm. None of the other genotypes were associated with change in E/e'. Compared to noncarriers, rs5522 G carriers also had a greater increase in left atrial area with placebo (β = 0.83; 95% CI: 0.17-1.48; p = 0.01) and a greater reduction in diastolic blood pressure with spironolactone (β = -3.56; 95% CI: -6.73 to -0.39; p = 0.03). Serum PIIINP levels were similar across rs5522 genotypes. CONCLUSIONS: Our results suggest that spironolactone attenuates progression of diastolic dysfunction associated with the NR3C2 rs5522 G allele. Validation of our findings is needed.
引用
- Dumeny L, Vardeny O, Edelmann F, et al. NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial. Pharmacotherapy. 2021. PMID: 34569641. doi:10.1002/phar.2626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。